Diamonds and Dogs

5/11/17

Valeant Pharma (VRX) moving higher again. After bad 2016 and a tough start to 2017, Valeant is moving in the right direction again following better than expected earnings last week and a big short position. Valeant is up 12% on an upgrade from RBC Capital Markets raising their price target to $19 a share.

Oh Snap! Internet chat site, Snap (SNAP) is down 20% following disappointing earnings. The company missed estimates by 26 cents as revenue missed as well. On a GAAP basis, the company lost $2.31 per share, $0.26 worse than estimates. Revenue rose 285.6% year over year to $149.6 million missing estimates of $158.32 million. Despite less-than-stellar growth reports, the 26-year-old Spiegel was defiant and laughed off concerns that Facebook was encroaching on Snapchat's turf, a move CNBC's Jim Cramer called "so arrogant."

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.